Company intelligence / Profile preview
Spyryx Biosciences
Durham, North Carolina, United Statesspyryxbio.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
Spyryx completed Phase 1 safety studies in healthy volunteers and CF patients. Their lead compound SPX-101 advanced to Phase 2 clinical trials (HOPE-1 study) with positive results reported from the first cohort in June 2018. The trial was designed as a 28-day, placebo-controlled study to establish treatment proof of concept independent of CFTR mutation.
- Therapeutic areas
- Pulmonology
- Modalities
- PeptidesInhaled therapeutics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Spyryx Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spyryx Biosciences.